Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rytary open-label extension in Parkinson's Disease
NCT01096186Phase 3Completed
- Sponsor
- Impax Laboratories
- Start
- Mar 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of carbidopa + levodopa in Parkinson's disease (PD), sponsored by Impax Laboratories. Started Mar 2010; status: completed.
02
Drugs
carbidopa + levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01096186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01096186.